
Biosimilars, which at the most simplistic level can be thought of as a type of generic option for a biologic, offer an opportunity to help reduce total biologic drug spend.
Timothy O'Shea, MS, PharmD, is a Clinical Pharmacist working at a regional health insurance plan on the east coast. Additionally he works per diem at a nationwide retail pharmacy chain. He graduated from MCPHS University - Boston in 2015 and subsequently completed a PGY-1 Managed Care Pharmacy Residency. He completed his M.S. in Health Services Administration, with a focus on Health Economics and Outcomes, in 2018. His professional interests include pharmacy legislation and managed care pharmacy. He can be followed on Twitter at @toshea125.

Biosimilars, which at the most simplistic level can be thought of as a type of generic option for a biologic, offer an opportunity to help reduce total biologic drug spend.

This article is the third in a series on difficult to pronounce drug names.

A number of landmark clinical studies on lipid lowering and cardiovascular health have been published, shaping how patients are treated.

This article will describe the unusual discovery of 5 commonly prescribed medications, many of which were through serendipitous events.

This is the seventh part of a series on how pharmacy professionals have been depicted on TV, both in a positive and a negative manner.

Everything pharmacists should know about gene therapy medications from current approved products to near and long-term pipeline information.

Published: January 2nd 2019 | Updated:

Published: February 2nd 2019 | Updated:

Published: March 31st 2019 | Updated:

Published: May 1st 2019 | Updated:

Published: October 11th 2019 | Updated:

Published: January 22nd 2020 | Updated: